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Genome-wide association studies (GWASs) have identified
multiple loci associated with cross-sectional eGFR, but a
systematic genetic analysis of kidney function decline over
time is missing. Here we conducted a GWAS meta-analysis
among 63,558 participants of European descent, initially from
16 cohorts with serial kidney function measurements within
the CKDGen Consortium, followed by independent
replication among additional participants from 13 cohorts.
In stage 1 GWAS meta-analysis, single-nucleotide
polymorphisms (SNPs) at MEOX2, GALNT11, IL1RAP, NPPA,
HPCAL1, and CDH23 showed the strongest associations for at
least one trait, in addition to the known UMOD locus, which
showed genome-wide significance with an annual change in
eGFR. In stage 2 meta-analysis, the significant association at
UMOD was replicated. Associations at GALNT11 with Rapid
Decline (annual eGFR decline of 3ml/min per 1.73m2 or
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more), and CDH23 with eGFR change among those with
CKD showed significant suggestive evidence of replication.
Combined stage 1 and 2 meta-analyses showed significance
for UMOD, GALNT11, and CDH23. Morpholino knockdowns of
galnt11 and cdh23 in zebrafish embryos each had signs of
severe edema 72h after gentamicin treatment compared
with controls, but no gross morphological renal
abnormalities before gentamicin administration. Thus, our
results suggest a role in the deterioration of kidney function
for the loci GALNT11 and CDH23, and show that the UMOD
locus is significantly associated with kidney function decline.
Kidney International (2015) 87, 1017–1029; doi:10.1038/ki.2014.361;
published online 10 December 2014
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Chronic kidney disease (CKD) is an important public health
problem affecting up to 10% of adults worldwide.1–3 Faster
rates of decline in estimated glomerular filtration rate
(eGFR), and entry into CKD stages of increasing severity,
are associated with an increased risk of cardiovascular and
all-cause mortality.4–9 Thus, recently issued guidelines on the
evaluation and management of patients with CKD have high-
lighted the importance of evaluating longitudinal measures
of renal function in addition to determining eGFR and
urinary albumin excretion at discrete time points.3
Traditional risk factors for CKD include diabetes and
hypertension, but these do not fully account for CKD risk.10
There is evidence for considerable clustering of CKD within
families11 and the heritability of eGFR has been estimated at
up to 36–75% in population-based studies.12 Using genome-
wide association studies (GWASs), multiple loci have been
identified in association with eGFR and CKD in both
European13–16 and non-European populations17,18 using data
from one time point. However, multiple lines of evidence
suggest that there may be unique genetic contributions to
renal function decline above and beyond baseline renal
function. First, there is substantial variability in the rate of
eGFR decline in studies of healthy persons as well as among
those with CKD.3,4,19,20 Second, we have previously shown
that some genetic loci associated with cross-sectional eGFR
are also associated with incident CKD (CKDi) even after
accounting for baseline eGFR.21 Finally, the genetic back-
ground has been shown to affect CKD progression in animal
models.22,23
Taken together, these data suggest that unique loci may
exist for renal function decline in addition to those identified
for a one-time measure of eGFR. Thus, we conducted a
GWAS meta-analysis among participants from 16 cohorts with
serial kidney function measurements within the CKDGen
Consortium, followed by independent replication among
additional participants from 13 cohorts.
RESULTS
Study participants
Changes in renal function over time were derived from
45,530 individuals who participated in stage 1 meta-analysis
of study-specific GWAS, and an additional 18,028 indepen-
dent individuals who participated in stage 2 meta-analysis
(Table 1). Details on study design and genotyping are provided
in Supplementary Tables S1 and S2 online, respectively.
At the baseline examination, the prevalence of CKD,
defined as eGFRo60ml/min per 1.73m2, ranged from 3.2 to
21.4% in stage 1 cohorts and from 0.2 to 23.9% in stage 2
replication cohorts. As expected, cohorts with lower mean
age at baseline tended to have a lower baseline prevalence of
CKD. Four kidney function decline traits were derived from
serial eGFR values in each study participant to model
mechanisms underlying different rates of kidney function
change over time: (i) annual decline of eGFR (eGFRchange,
in ml/min per 1.73m2 decline per year; a positive value
represents a decline in eGFR, whereas a negative value
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represents a rise in eGFR over time); (ii) CKDi to select
individuals with a decline in kidney function to the clinical
outcome CKD stage 3 or higher (CKDi, cases defined as those
free of CKD at baseline but eGFRo60ml/min per 1.73m2
during follow-up); (iii) CKDi with additionally at least a 25%
eGFR decline from baseline to select individuals reaching
CKD stage 3 after a sizeable decline in kidney function
(CKDi25);24 and (iv) rapid eGFR decline to select individuals
with the highest risk of adverse outcomes (Rapid Decline,
cases defined as those with annual eGFR decline X3ml/min
per 1.73m2).5 Most cohorts showed a decline in kidney
function over time (Table 1). The distribution of all four
traits in stage 1 and stage 2 cohorts can be found in
Supplementary Table S3 online.
Heritability of eGFR change
The heritability of eGFR change in the Framingham Heart
Study was estimated as 38%, after adjusting for age, sex, and
baseline eGFR.
Stage 1 meta-analysis of GWAS of measures of kidney
function change over time
Stage 1 GWAS meta-analysis was performed in all samples for
all four traits. Two secondary association analyses were
performed to account for potentially different rates of kidney
function decline in those with and those without CKD: (i)
eGFRchange stratified by baseline CKD status and (ii) Rapid
Decline in only those without baseline CKD; too few indivi-
duals with CKD fulfilled the Rapid Decline criteria to perform
this analysis. Supplementary Figure S1 online shows the
Manhattan and QQ-plots of the stage 1 meta-analysis of each
trait. The genomic control factor ranged from 1.007 to 1.05,
suggesting negligible evidence for population stratification.
In GWAS meta-analysis of stage 1 cohorts, the minor T
allele of rs12917707 at the UMOD locus, previously identified
by GWAS to be associated with higher eGFR in cross-sectional
analysis,14 was associated with an increase in eGFR over time
at a genome-wide significance level (P¼ 2.610 14, Table 2),
and showed at least nominally significant, direction-consis-
tent association with all other analyzed phenotypes (Supple-
mentary Table S4 online). In addition, SNPs at the novel
CDH23, GALNTL5/GALNT11, MEOX2, IL1RAP/OSTN,
C2orf48/HPCAL1, and NPPB/NPPA loci were associated with
at least one of the analyzed traits at a significance level of
Po10 6 (Table 2). Thus, a total of seven SNPs were moved
forward to stage 2 meta-analysis. These SNPs mostly showed
high imputation quality in each cohort or were genotyped
de-novo (Supplementary Table S5 online), and showed low
between-study heterogeneity (I2o25%).
Stage 2 meta-analysis
Of the seven loci moved forward for stage 2 meta-analysis,
only rs12917707 at UMOD was significantly associated
with the stage 1 trait after correcting for multiple testing
(P¼ 4.7*10 5). Two further SNPs showed suggestive
significance (one-sided Po0.05) with their respective stage Ta
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1 trait: rs875860 in CDH23 with eGFRchange in those with
CKD at baseline, and rs1019173 at GALNTL5/GALNT11 with
Rapid Decline (Table 2). There was no significant hetero-
geneity between studies for these two SNPs (rs875860: I2¼ 9.7%,
P¼ 0.34; rs1019173: I2¼ 32.4%, P¼ 0.12) or for the other
SNPs analyzed in the stage 2 meta-analysis (I2o30.0%).
The SNP rs1019173 is located in an intron in the GALNTL5
gene, and lies in a linkage disequilibrium block spanning the
genes GALNT11, MLL3, CCT8L, and part of the GALNTL5
gene (Figure 1a). The SNP in CDH23, rs875860, is an intronic
SNP in a linkage disequilibrium block whose boundaries lie
within the coding region of the CDH23 gene (Figure 1b).
In the combined meta-analysis of these three SNPs from
both stage 1 and stage 2 cohorts, there was no evidence of
between-study heterogeneity in the combined meta-analysis
(I2o25%). Only the SNP at UMOD showed genome-wide
significant association (rs12917707, P¼ 1.210 16) in the
combined stage 1 and stage 2 analysis, whereas there was
suggestive evidence of significance for the two novel loci iden-
tified in stage 1 (rs875860 in CDH23: P¼ 1.510 6 for the
association with eGFRchange in those with CKD; rs1019173 at
GALNTL5/GALNT11: odds ratio¼ 0.91 for the A allele,
P¼ 2.210 7 for the association with Rapid Decline).
Functional validation of novel loci in zebrafish
To investigate the role of the two suggestive novel loci in
vertebrate kidney development and function and to bolster
confidence in the nominally significant statistical associations in
the replication studies, we knocked down the corresponding
genes in the zebrafish using antisense morpholino (MO) tech-
nology. We focused on the CDH23 region and the block contain-
ing GALNTL5, GALNT11, MLL3, and CCT8L1. For the latter
region, we focused on GALNT11 andMLL3, because there are no
zebrafish GALNTL5 and CCT8L1 orthologs. Further, we investi-
gated the effect of MO knockdown of umod. Following MO
injection at the 1-cell stage, we performed in situ hybridization for
the established renal markers pax2a (global kidney) and nephrin
(podocytes) at 48h post fertilization (h.p.f.). Compared with
control embryos, cdh23, galnt11, mll3a, mll3b, and umod mor-
phants did not display significant defects in glomerular or tubule
gene expression (Figure 2a, n425 embryos per MO injection).
It is possible that morphant embryos develop a kidney
function decline phenotype only after exposure to a nephro-
toxin, despite observing no differences in renal marker expres-
sion at 48 h.p.f. Accordingly, after MO injection, we injected
embryos with gentamicin at 48 h.p.f. and observed edema pre-
valence and severity over the next 3 days. In control embryos,
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Figure 1 | Regional association plots of the novel loci identified by genome-wide association study (GWAS) of kidney function decline
traits. Negative log10 P values are plotted vs. genomic position (build 36, hg18). The lead single-nucleotide polymorphism (SNP) in each region
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gentamicin injection predictably resulted in a majority of
embryos developing minor (cardiac) edema by 24h post injec-
tion (h.p.i.) (Figure 2b–d). In comparison, cdh23 and galnt11
morphants developed significantly more severe (cardiac, inte-
stinal, and ocular) and more frequent edema (Figure 2b–d).
Specifically, whereas 10% of control embryos developed severe
edema by 72h.p.i., 43% of cdh23 morphants (P¼ 0.009) and
55% of galnt11 morphants (P¼ 0.001) developed severe edema
at this time point. Additionally, a significant proportion of
cdh23 (33%, P¼ 0.035) and galnt11 morphant embryos (46%,
P¼ 0.005) injected with gentamicin developed edema earlier
compared with controls at 5 h.p.i. In contrast, knockdown
of mll3 or umod affected neither kidney development nor
susceptibility to gentamicin (Figure 2b and c). Taken together,
these data demonstrate that knockdown of cdh23 and galnt11
results in altered renal function after a nephrotoxic insult.
Interrogation of novel loci in eSNP databases and the Chronic
Renal Insufficiency Cohort (CRIC) study
We interrogated eSNP databases for evidence of SNPs at the
CDH23 and GALNTL5/GALNT11 loci to evaluate an effect
on gene expression25 but found no relevant associations.
Similarly, annotation information provided by functional
annotation of genetic variants from high-throughput
sequencing data (ANNOVAR)26 did not yield genetic
variants of potential functional interest within 500 kb of
and in linkage disequilibrium (r240.8 based on HapMap
release 22) with the index SNPs.
In Caucasian participants of the CRIC study, a prospective
study of patients with CKD at baseline,27 neither SNPs in
GALNTL5/GALNT11 nor SNPs in CDH23 were associated
with eGFRchange (n¼ 1476) or time to a composite renal
event that consisted of incident end-stage renal disease or
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halving of eGFR (n¼ 1585, with a total of n¼ 178 events;
results not shown).
DISCUSSION
Key findings
Our key findings are fourfold. First, we estimate the herita-
bility of eGFR decline as being 38% in the general population
of European descent, providing a rationale to search for
genetic variants associated with kidney function decline. Second,
we extend evidence of a known locus (UMOD) previously
associated with CKDi and end-stage renal disease21,28 by
showing genome-wide significant association with kidney
function change. Third, we have identified two novel genetic
loci (CDH23 and GALNTL5/GALNT11) with suggestive asso-
ciation with kidney function decline phenotypes. Finally, we
show that knockdown of the two novel loci in zebrafish
renders the nephron susceptible to a nephrotoxic insult.
Our findings in the context of the literature
We extend the current literature by performing the first large-
scale GWAS of renal function decline traits in the general
population. Previous studies analyzing progression of renal
disease in African Americans,29–32 individuals of European
descent,21 healthy nurses,33 and patients with diabetes,34,35
hypertension,31 IgA nephropathy,36,37 and end-stage renal
disease21 focused only on candidate genes.
The SNP in UMOD has previously been identified in a
GWAS of eGFR measured at one time point,14 and was
significantly associated with CKDi and end-stage renal
disease in a candidate gene study21 and with salt-sensitive
hypertension and kidney damage in rodents and humans.38
Our data extend this knowledge base by providing strong
evidence that genetic variation at the UMOD locus affects
different definitions of kidney function decline.
For Rapid Decline, the associated region on chromosome
7 contains the genes GALNTL5, GALNT11, MLL3, and
CCT8L1, with our zebrafish data suggesting GALNTL5 and
GALNT11 as the genes of interest. GALNTL5 encodes the
putative polypeptide N-acetylgalactosaminyltransferase-like
protein 5, which by similarity has a presumed role in
O-linked oligosaccharide biosynthesis. Polypeptide N-acet-
ylgalactosaminyltransferase 11, encoded by GALNT11, is a
glycosyl transferase that catalyzes the initial reaction in
O-linked oligosaccharide biosynthesis. Studies in Xenopus
support a role of the gene product in left–right patterning by
modulating Notch1 signaling, thus establishing the crucial
balance between motile and immotile cilia, and it is also
expressed in the developing kidney of zebrafish.39,40 Our data
suggest that galnt11 is not essential for kidney development
but protects against susceptibility from nephrotoxins.
The region of chromosome 7 also contains a locus
(rs7805747 in PRKAG2) that was previously identified in a
GWAS meta-analysis of cross-sectional eGFR.15 However, this
SNP is independent of rs1019173 (r2¼ 0.002, D0 ¼ 0.061 in
the 1000 Genomes Pilot Version 1, hg18); therefore, the novel
locus identified in the present study is unlikely tagging the
PRKAG2 locus. Moreover, conditional analysis using genotypes
from both SNPs from individual level data from the ARIC
study showed that the association between rs1019173 and
Rapid Decline is unchanged when controlling for rs7805747
(data not shown).
The other locus identified from this study is an intronic
SNP in CDH23 that is nominally associated with eGFR
change in those with CKD at baseline. CDH23 encodes
cadherin 23, a glycoprotein of the cadherin family. Cadherin
23 and protocadherin 15, encoded by PCDH15, form the tip-
links spanning the stereocilia of the inner ear’s hair cells.
These tip-links are key contributors to the mechanosensory
transduction in hair cells required for hearing.41 Rare muta-
tions of CDH23 cause progressive, nonsyndromic deafness
(DFNB12, MIM # 601386)42–44 or Usher Syndrome 1D,
characterized by profound deafness, vestibular dysfunction,
and retinitis pigmentosa (MIM # 601067). The transmem-
brane protein cadherin 23 is expressed in many tissues,
including the kidney,44,45 where it is found predominantly in
the tubulointerstitium.46 Although a kidney phenotype has
not been reported for patients with DFNB12 or Usher syn-
drome, our zebrafish data provide evidence that cadherin 23
has a role in protecting from susceptibility to nephrotoxins,
while not being essential for nephrogenesis.
Implications
Our GWAS findings point toward two novel gene loci, CDH23
and GALNTL5/GALNT11, and one previously identified
locus (UMOD) as being associated with kidney function
decline. The zebrafish experiments support a role of the two
newly identified loci in increasing renal susceptibility to
nephrotoxic insults and may indicate that a perturbation
model could serve as a model of longitudinal kidney function
decline. In a previous work, we have shown that knockdown
of two genes identified by GWAS of cross-sectional eGFR,
mpped2 and casp9, resulted in abnormal kidney development,
with susceptibility to gentamicin only in casp9 knockdown.16
Taken together, our current and previous data highlight the
differential role of genes in affecting kidney development,
function, and susceptibility to damage.
Strengths and limitations
The strengths of this study include the large sample size of renal
function decline traits, follow-up in independent samples,
analysis of several definitions of kidney function decline, and
validation in zebrafish. Some limitations warrant mention. Even
though we addressed interassay differences of serum creatinine
measurement by calibrating creatinine to representative Na-
tional Health and Nutrition Examination Study (NHANES)
standards, several other factors causing imprecision in defining
kidney function decline phenotypes may have reduced our
statistical power to identify genome-wide significant associa-
tions: (i) despite our use of different renal function decline
definitions, all featured in current guideline statements,3 there is
no standard definition of renal function decline; (ii) kidney
function trajectories are less well defined with two vs. several
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serum creatinine measurements given that renal function
change may not be linear over time3 and there may be day-
to-day alterations in glomerular filtration rate (GFR); (iii) GFR
estimation equations are known to be imprecise, especially at
GFR460ml/min per 1.73m2; (iv) we observed heterogeneity in
design between studies, including a wide range of length of
follow-up. We cannot rule out that low statistical power also
accounts for the negative finding in the CRIC study. Further,
our findings, obtained mainly in general population cohorts,
provide novel insights into mechanisms of kidney function
decline, but may not be generalizable to cohorts enriched for
CKD. This limitation deserves particular attention because of
the unexpected observation that, in most cohorts, the subgroup
with baseline CKD (defined as eGFRo60ml/min per 1.73m2)
showed a mean increase in eGFR over time irrespective of
length of follow-up interval. This may indicate that, in the
CKD subgroup of these cohorts, a baseline eGFRo60ml/min
per 1.73m2 may not represent progressive CKD with active
disease but rather stable disease or imprecise GFR estimation.
This highlights that more work with expanded data sets and
functional models are necessary to further elucidate the
genetics of CKD initiation and progression in population-
based studies. Finally, the role of genes contributing to aging
and chronic disease in humans may not be entirely modeled
by transient MO knockdown and observation of a develop-
mental phenotype: whereas zebrafish allows high throughput
modeling of the effects of gene knockdown in a vertebrate
organism, the developmental role of specific genes may well
be different from homeostatic organ maintenance in the
adult. Specifically, umod may not have a relevant role in
zebrafish renal development or toxin susceptibility.
CONCLUSION
In a large GWAS of kidney function decline phenotypes in
individuals of European descent, we showed that a SNP in
UMOD is associated with kidney function decline pheno-
types, and that there is suggestive statistical evidence for
two novel loci (GALNTL5/GALNT11 and CDH23). Zebrafish
experiments at the two novel loci suggest roles in the
deterioration of kidney function after acute injury. Given the
complexity of the kidney function decline phenotype, further
interrogation of these regions is warranted.
MATERIALS AND METHODS
Ethics statement
In all studies, all participants gave informed consent. All studies
were approved by their responsible Research Ethics Committees.
Phenotype definition
Serum creatinine was measured at a minimum of two time points
spaced several years apart (2.0–22.2 years, median 5.6 years). In
almost all studies, there were only two serum creatinine measure-
ments in total. To be consistent across studies, we used each
individual’s two creatinine measurements with the longest follow-up
in between for phenotype creation in all cohorts (see below). Baseline
and follow-up serum creatinine were calibrated to the US nationally
representative NHANES data in all discovery and replication studies
to account for between-laboratory variation.47 In order to be
consistent with our prior work, GFR based on serum creatinine
(eGFRcrea) was estimated using the four-variable MDRD Study
Equation. eGFRcrea values o15ml/min per 1.73m2 were set to 15,
and those 4200 were set to 200ml/min per 1.73m2.
Several phenotypes were used to model different mechanisms
involved in the change in renal function over time, using each
individual’s two serum creatinine measurements with the longest
follow-up. The continuous phenotype eGFRchange, modeling
annual change in kidney function, was calculated by subtracting
the eGFR at follow-up from the eGFR at baseline and then dividing
by the number of years of follow-up for each participant. Thus, a
positive value of eGFRchange corresponds to a decline in kidney
function over time, whereas a negative value of eGFRchange corre-
sponds to an increase in kidney function over time. Three dichoto-
mous phenotypes were calculated to model kidney function decline
phenotypes with different clinical implications:5,24 for Rapid Decline,
cases were defined as individuals with a rapid decline in kidney
functionX3ml/min per 1.73m2 per year, and controls as those with
a kidney function decline o3ml/min/1.73m2 per year.6 For CKDi,
cases were defined as participants with eGFR at baseline X60ml/
min per 1.73m2 declining to an eGFR at follow-upo60ml/min per
1.73m2; a more stringent definition of CKDi (CKDi25) is restricted
to CKDi cases with a decline in eGFRX25% at follow-up. For both
CKDi and CKDi25, controls were defined as those with an eGFR
X60ml/min per 1.73m2 at baseline and follow-up.
Heritability of eGFR in the Framingham Heart Study
Heritability of eGFRchange was calculated with the family data of
the Framingham Heart Study using the variance components
analysis implemented in SOLAR.48 eGFRchange was calculated by
taking follow-up eGFR (obtained between 2005 and 2008) and
subtracting baseline eGFR (obtained in 1995–1998), divided by the
number of years of follow-up. Residuals were created after adjusting
for age, sex, baseline eGFR, and principal components as necessary.
With residuals as response variable, a variance components model
with an additive genetic and a random environmental variance com-
ponent was fitted, where the correlation among relatives attributable
to the genetic component is assumed proportional to the kinship
coefficient matrix. Heritability is calculated as the ratio of the
estimated genetic variance to the total phenotypic variance.
Definition of strata
Kidney function decline is known to differ depending on the level of
baseline eGFR. Thus, eGFRchange was analyzed (i) in the overall
sample (eGFRchange overall), (ii) in those with eGFR X60ml/min
per 1.73m2 at baseline (eGFRchange noCKD), and (iii) in those
with eGFRo60ml/min per 1.73m2 at baseline (eGFRchange withCKD).
Rapid Decline was analyzed in the overall sample (Rapid Decline
overall) and in those with eGFRX60ml/min per 1.73m2 at baseline
(Rapid Decline noCKD). CKDi and CKDi25 were analyzed in the
overall sample only.
Stage 1 genome-wide association analyses
All participating studies used a uniform analysis plan and each trait
was created using standard programming commands that were pro-
vided to collaborating studies. The continuous trait (eGFRchange)
was analyzed by linear regression and the dichotomous traits by
logistic regression (Rapid Decline, CKDi, CKDi25). Models included
the allelic dosage at each marker from imputed study data consisting
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of 2.5 million HapMap-II SNPs49 on average, based on imputations
with different programs and reference panels. Details of genotyping
and imputation in each study are shown in Supplementary Table S2
online. We used the additive genetic model, adjusted for age and sex,
baseline eGFR, and, where applicable, for study site and principal
components.
Stage 1 meta-analysis
For our stage 1 analysis, we used aggregated statistics of 16
population-based GWASs of individuals of European ancestry for
each of the longitudinal traits: eGFRchange overall, eGFRchange
noCKD, eGFRchange with CKD, Rapid Decline overall, Rapid Decline
noCKD, CKDi, and CKDi25. All 16 stage 1 studies contributed data
to every trait, except for the AMISH study, which provided data to
eGFRchange overall and eGFRchange no CKD only because of low
number of CKD cases at baseline and follow-up.
All input files underwent quality control using the GWAtoolbox
package in R (http://www.eurac.edu/GWAtoolbox.html)50 before
including them into the meta-analysis. Study data were meta-analyzed
assuming fixed effects and using inverse-variance weighting. Thus, the
pooled effect bpooled is estimated as
P
i
bi = s:e:
2
i
1 = s:e:2
i
, where b and s.e. are the
effect and standard error of the SNP on the outcome in the ith study.
The meta-analyses were performed by METAL. We performed genomic
control correction if the inflation factor l in the study files was greater
than 1 (first genomic control correction) or if it was greater than 1 in
the meta-analysis result (second genomic control correction).51
Next, we created a list of independent SNPs (pairwise r2o0.2,
HAPMAP II release 22) that had a genomic control-corrected
P-value o10 6 and minor allele frequency 45% in stage 1 meta-
analysis and were present in at least 85% of the contributing studies.
Stage 2 meta-analysis
The stage 2 meta-analysis of SNPs identified in stage 1 was
performed on the same phenotypes and using the same analysis plan
as the stage 1 analysis, and was based on in silico genetic data or on
de novo genotyped variants. Details on each stage 2 study’s geno-
typing and imputation platforms are shown in Supplementary
Table S2 online. In addition, we also performed a combined inverse-
variance weighted fixed-effects stage 1 and stage 2 meta-analysis
using individual study files as input. Studies with less than 50 cases
for a dichotomous trait or with an overall sample size of less than 50
for a continuous trait were excluded from the meta-analyses of the
corresponding trait. SNPs with a stage 2 meta-analysis one-sided
P-value o0.05 and effect direction consistency with the stage 1
meta-analysis effect direction were defined as showing nominally
significant evidence of replication. The I2 statistic was computed to
assess heterogeneity between studies.
Zebrafish functional experiments
Zebrafish were maintained according to established Institutional
Animal Care and Use Committees protocols. Zebrafish were injected
at the 1-cell stage with 2 nl of 400 mM MO (GeneTools, Philomath,
OR) designed to block the ATG start site or an exon–intron splice
site of the target gene (Supplementary Table S6 online). Embryos
were fixed in 4% paraformaldehyde at the appropriate stages for
in situ hybridization using well-established protocols (http://zfin.org/
ZFIN/Methods/ThisseProtocol.html). Renal gene expression was
visualized using established markers for pax2a (global kidney) and
nephrin (podocytes).52,53 The number of embryos displaying abnormal
renal gene expression was compared with uninjected control embryos,
and statistical significance was determined by Fisher’s exact test. For the
gentamicin nephrotoxin experiment, embryos were injected with MO
at the 1-cell stage and then injected with 5nl of 10mg/ml gentamicin
prepared from one stock solution in the cardiac sinus venosus at
48h.p.f. after being anesthetized in a 1:20 dilution of 4mg/ml Tricaine
in embryo water. Live embryo development and edema prevalence were
documented over the next 3 days.
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Supplementary Table 1. Study-specific methods and full acknowledgments – stage 1 and stage 2 cohorts.  
Study name 
(key 
references) 
Study 
design 
Total 
genotype
d sample 
size 
Study 
exclusions or 
disease 
enrichment 
Exclusions 
Creatinine 
measurements 
Serial 
creatinine 
measurement
s 
Acknowledgments and funding source 
Stage 1 
cohorts 
       
AGES [1] 
Population-
based 
3,664 None 
Sample exclusion 
criteria included 
sample failure, 
genotype mismatch 
with reference panel, 
and sex mismatch, 
resulting in clean 
genotype data on 
3,219 individuals. 
AGES: Serum 
creatinine was 
measured 
using the 
Roche-Hitachi 
912 instrument 
with Roche 
Creatinine Jaffé 
compensated 
method; Roche 
Diagnostics, 
Mannheim, 
Germany. 
AGESII: Serum 
creatinine was 
measured 
using the 
Roche-Hitachi 
P-Module 
instrument with 
Roche 
Creatininase 
Plus assay. 
Serum 
creatinine a 
was measured 
at baseline 
(AGES:2002-
2006), and at a 
follow-up five 
years later 
(AGESII:2007-
2011). 
Individuals 
were recruited 
in the same 
order. 
AGES: This study has been funded by NIH contract 
N01-AG-1-2100, the NIA Intramural Research 
Program, Hjartavernd (the Icelandic Heart 
Association), and the Althingi (the Icelandic 
Parliament). The study is approved by the Icelandic 
National Bioethics Committee, VSN: 00-063. The 
researchers are indebted to the participants for their 
willingness to participate in the study 
Amish studies 
[2,3]  
Population-
based 
founder 
cohort 
1,264 None 
Age<20, severe 
chronic disease, call 
rate<95%, 
pHWE<10E-6 
Modified kinetic 
Jaffé reaction 
All had 
baseline 
measures. 
Timing for 
repeat 
measures was 
variable 
AMISH: The Amish studies are supported by grants 
and contracts from the NIH including R01 AG18728 
(Amish Longevity Study),  R01 HL088119 (Amish 
Calcification Study), U01 GM074518-04 (PAPI 
Study), U01 HL072515-06 (HAPI Study), U01 
HL084756 and NIH K12RR023250 (University of 
Maryland MCRDP), NIH P30 DK072488 (Clinical 
Nutrition Research Unit), the University of Maryland 
General Clinical Research Center, grant M01 RR 
16500 and the Baltimore Veterans Administration 
Medical Center Geriatrics Research and Education 
Clinical Center. We thank our Amish research 
volunteers for their long-standing partnership in 
research, and the research staff at the Amish 
Research Clinic for their hard work and dedication. 
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Atherosclerosis 
Risk in 
Communities 
(ARIC) Study [4] 
Population-
based 
9,713 of 
European 
ancestry 
None 
Of the 9713 
genotyped individuals 
of European ancestry, 
we excluded 658 
individuals based on 
discrepancies with 
previous genotypes, 
disagreement 
between reported and 
genotypic sex, one 
randomly selected 
member of a pair of 
first-degree relatives, 
or outlier based on 
measures of average 
DST or more than 8 
SD away on any of 
the first 10 principal 
components. 
Modified kinetic 
Jaffe reaction 
(serum) 
Serum 
creatinine from 
visits 1, 2, and 
4 were used for 
phenotype 
definition 
The Atherosclerosis Risk in Communities Study is 
carried out as a collaborative study supported by 
National Heart, Lung, and Blood Institute contracts 
(HHSN268201100005C, HHSN268201100006C, 
HHSN268201100007C, HHSN268201100008C, 
HHSN268201100009C, HHSN268201100010C, 
HHSN268201100011C, and 
HHSN268201100012C), R01HL087641, 
R01HL59367 and R01HL086694; National Human 
Genome Research Institute contract 
U01HG004402; and National Institutes of Health 
contract HHSN268200625226C. The authors thank 
the staff and participants of the ARIC study for their 
important contributions. Infrastructure was partly 
supported by Grant Number UL1RR025005, a 
component of the National Institutes of Health and 
NIH Roadmap for Medical Research. A.K. was 
supported by the grant KO3598/2-1 (Emmy Noether 
Programme) of the German Research Foundation. 
ASPS [5,6]  
 
Prospective, 
single center 
study 
922 
History of 
neuropsychiatric 
disease, 
previous stroke 
and/or TIA, and 
dementia 
Of the 922 
participants who 
underwent 
genotyping, 74 with 
sample call rate < 
98% were excluded 
resulting in a total of 
848 genotyped 
individuals 
Modified kinetic 
Jaffe reaction 
Serum 
creatinine was 
measured at 
baseline and at 
the 3 year  and 
6 year  follow-
up. 
ASPS: The research reported in this article was 
funded by the Austrian Science Fond (FWF) grant 
number P20545-P05 and P13180. The Medical 
University of Graz supports the databank of the 
ASPS. The authors thank the staff and the 
participants of the ASPS for their valuable 
contributions. We thank Birgit Reinhart for her long-
term administrative commitment and Ing Johann 
Semmler for the technical assistance at creating the 
DNA-bank. 
Cardiovascular 
Health Study 
(CHS) [7,8]  
Prospective, 
population-
based 
3,397 
In total, 1908 
persons were 
excluded from 
the GWAS study 
sample due to 
the presence at 
study baseline of 
coronary heart 
disease, 
congestive heart 
failure, periphe-
ral vascular 
disease, valvular 
heart disease, 
stroke or tran-
sient ischemic 
attack or lack of 
available DNA 
This study is based 
upon genotyping 
results from 3,329 
CHS Caucasian 
participants, who 
were free of clinical 
cardiovascular 
disease at baseline, 
consented to genetic 
testing, and had DNA 
available for geno-
typing. Genotypes 
were called using the 
Illumina BeadStudio 
software. Genotyping 
was successful in 
3,291 persons. 
Colorimetric 
method 
(Ektachem 700, 
Eastman 
Kodak) (serum) 
The serum 
creatinine at 
baseline and at 
the 5 year 
follow-up were 
used to define 
the longitudinal 
renal 
phenotypes. If 
data from the 5 
year follow-up 
were missing, 
the data from 
the 9 year 
follow-up were 
used. 
The CHS research reported in this article was 
supported by contract numbers N01-HC-85079 
through N01-HC-85086, N01-HC-35129, N01 HC-
15103, N01 HC-55222, N01-HC-75150, N01-HC-
45133, grant numbers U01 HL080295 and R01 
HL087652 from the National Heart, Lung, and 
Blood Institute, with additional contribution from the 
National Institute of Neurological Disorders and 
Stroke. A full list of principal CHS investigators and 
institutions can be found at http://www.chs-
nhlbi.org/pi.htm. DNA handling and genotyping was 
supported in part by National Center for Research 
Resources grant M01RR00425 to the Cedars-Sinai 
General Clinical Research Center Genotyping core 
and National Institute of Diabetes and Digestive and 
Kidney Diseases grant DK063491 to the Southern 
California Diabetes Endocrinology Research 
Center. 
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Cohorte 
Lausannoise 
(CoLauS) [9] 
 
Prospective, 
population-
based 
5,636 
Individuals <35 
years were no 
included 
Call rate <90%, 
related individuals, 
resulting in 5435 
genotyped individuals 
in total 
Modified kinetic 
Jaffe reaction 
(maximum inter 
and intra-batch 
CVs: 2.9% – 
0.7%) (Roche 
Diagnostics, 
Switzerland) in 
the serum 
Participants 
who took part 
at the baseline 
CoLaus 
examination 
were invited to 
a 5-year follow-
up 
examination; 
which is still 
ongoing and 
covers the 
period 2009 to 
2012. 1931 
COLAUS 
participants 
had data 
available at the 
time of the 
stage 1 
discovery; and 
2238 additional 
COLAUS 
participants 
had data 
available to be 
included at the 
time of the 
replication 
The CoLaus study received financial contributions 
from GlaxoSmithKline; the Faculty of Biology and 
Medicine of Lausanne; the Swiss National Science 
Foundation (33CSCO-122661; 3200BO-111361/2; 
3100AO-116323/1;310000-112552). M.B is 
supported by the Swiss School of Public Health 
Plus. 
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Framingham 
Heart Study 
(FHS) [10-12]  
Prospective, 
family-based 
9,300 None 
Of the 9,274 
participants who 
underwent 
genotyping, we made 
the following 
exclusions: sample 
call rate <97% 
(n=666), genotype 
heterozygosity > 5 
standard deviations, 
and ambiguous family 
data (n=127). This 
resulted in a total of 
8,481 genotyped 
individuals. 
Modified kinetic 
Jaffe reaction 
(serum) 
Participants for 
the current study 
include 
individuals of 
European 
descent from the 
original cohort 
who attended 
cohort exam 15 
(1977 to 1979) 
and exam 24 
(1995 to 1998) 
[n=548], as well 
as participants 
from the offspring 
cohort who 
attended the sixth 
(1995 – 1998) 
and the eighth 
exams (2005-
2008) [n=2234]. 
Incident CKD 
was defined as 
cases of CKD 
(eGFR <60 
ml/min/1.73m2) 
present at exam 
cycle 24 (original 
cohort) and exam 
cycle 8 (offspring 
cohort) in 
individuals free of 
CKD at the 
earlier respective 
exam (i.e. exam 
15 for the original 
cohort and exam 
6 for the offspring 
cohort). In total 
2523 participants 
had complete 
baseline and 
follow-up 
information, and 
were successfully 
genotyped for 
GWA analysis. 
FHS: This research was conducted in part using 
data and resources from the Framingham Heart 
Study of the National Heart Lung and Blood 
Institute of the National Institutes of Health and 
Boston University School of Medicine. The 
analyses reflect intellectual input and resource 
development from the Framingham Heart Study 
investigators participating in the SNP Health 
Association Resource (SHARe) project. This work 
was partially supported by the National Heart, Lung 
and Blood Institute's Framingham Heart Study 
(Contract No. N01-HC-25195) and its contract with 
Affymetrix, Inc for genotyping services (Contract 
No. N02-HL-6-4278). A portion of this research 
utilized the Linux Cluster for Genetic Analysis 
(LinGA-II) funded by the Robert Dawson Evans 
Endowment of the Department of Medicine at 
Boston University School of Medicine and Boston 
Medical Center. 
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GENOA [13-15]  
Family-
based 
1,553 
5 Non-white, 1 
Missing Exam 
For the Affymetrix 6.0 
data, we excluded: 25 
subjects who failed 
pre-processing, 123 
with Contrast QC < 
0.4, 2 for inconsistent 
relatedness, 11 
identical twins. We re-
ran the samples that 
failed pre-processing 
or the Contrast QC 
filter on the Affymetrix 
6.0 data along with 50 
that had passed. Of 
these samples, 19 
failed genotyping 
completely, 9 had call 
rate < 0.95, 2 had 
inconsistent 
relatedness, and 2 
were identical twins. 
Of these 1509 
remaining samples, 
346 samples do not 
have serum creati-
nine information. Our 
final data had 1163 
samples with geno-
type and phenotype 
data. 
We performed 
a calibration 
study between 
serum 
creatinine 
levels in the 1st 
GENOA 
examination 
(1996-2000) 
assayed on a 
Monarch 
autoanalyzer 
(uncompensate
d rate-Jaffe 
reaction) and in 
the 2nd and 3rd 
GENOA 
examinations 
assayed on a 
Hitachi 911 
autoanalyzer 
(compensated 
rate-Jaffe 
reaction). 
Serum 
creatinine was 
measured at 
baseline, at 5 
year and 10 
year follow-up. 
GENOA: This research was partially supported by 
the National Heart Lung and Blood Institute of the 
National Institutes of Health R01 HL-87660. 
Health ABC [16] 
Prospective 
cohort study 
888 None 
Samples were 
excluded from the 
dataset for the 
reasons of sample 
failure, genotypic sex 
mismatch, and first-
degree relative of an 
included individual 
based on genotype 
data. 
Colorimetric 
technique on a 
Johnson & 
Johnson 
VITROS 950 
Chemistry Ana-
lyzer (Johnson 
& Johnson, 
New 
Brunswick, NJ, 
USA) using the 
enzymatic 
method. 
Serum 
creatinine was 
measured at 
year1 and year 
10 . 
The Health Aging and Body Composition Study 
(Health ABC) was funded by the National Institutes 
of Aging. This research was supported by NIA 
contracts N01AG62101, N01AG62103, and 
N01AG62106. The genome-wide association study 
was funded by NIA grant 1R01AG032098-01A1 to 
Wake Forest University Health Sciences and 
genotyping services were provided by the Center 
for Inherited Disease Research (CIDR). CIDR is 
fully funded through a federal contract from the 
National Institutes of Health to The Johns Hopkins 
University, contract number HHSN268200782096C. 
This research was supported in part by the 
Intramural Research Program of the NIH, National 
Institute on Aging. 
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JUPITER [17] Clinical trial 12,649 None 
Successfully 
genotyped samples 
had >98.5% of SNPs 
genotyped. In 
JUPITER, the total 
number genotyped 
samples was 12,649 
among which 8,782 
had self-reported 
European ancestry 
that could be 
confirmed by the 
MDS procedure in 
PLINK. 
Creatinine 
analyses were 
performed in 
JUPITER core 
central 
laboratories 
using the 
Roche Modular 
Analytics 
Chemistry 
System with 
Roche 
creatinine 
reagents 
(modified Jaffé 
reaction with 
rate blanking). 
Intra- and inter-
assay 
coefficients of 
variation were 
4.1% and 3.9%, 
respectively. 
The 
phenotypes 
were calculated 
using two 
creatinines per 
patient, taken 
at the first and 
last exam of 
each patient in 
the Jupiter 
study.  
The JUPITER trial and the genotyping were 
supported by AstraZeneca 
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KORA S3/F3 
KORA S4/F4 
[18,19]  
Prospective 
population-
based 
F3: 1644 
F4: 1814 
None None 
S3 and S4: 
enzymatic 
assay. 
F3 and F4: 
Modified kinetic 
Jaffe reaction 
Serum 
creatinine was 
measured at 
baseline and at 
the 10 year 
(F3) and 7 year 
(F4) follow-up. 
KORA studies: The genetic epidemiological work 
was funded by the NIH subcontract from the 
Children’s Hospital, Boston, US, (H.E.W., I.M.H, 
prime grant 1 R01 DK075787-01A1), the German 
National Genome Research Net NGFN2 and 
NGFNplus (H.E.W. 01GS0823; WK project A3, 
number 01GS0834), the Munich Center of Health 
Sciences (MC Health) as part of LMUinnovativ, and 
by the Else Kröner-Fresenius-Stiftung 
(P48/08//A11/08 to C.A.B. and B.K.K.; 2012_A147 
to CAB and IMH). The kidney parameter 
measurements in F3 were funded by the Else 
Kröner-Fresenius-Stiftung (C.A.B., B.K.K.) and the 
Regensburg University Medical Center, Germany; 
in F4 by the University of Ulm, Germany (W.K.). 
Genome wide genotyping costs in F3 and F4 were 
in part funded by the Else Kröner-Fresenius-
Stiftung (C.A.B., B.K.K.). De novo genotyping in F3 
and F4 were funded by the Else Kröner-Fresenius-
Stiftung (C.A.B., IMH). The KORA research 
platform and the MONICA Augsburg studies were 
initiated and financed by the Helmholtz Zentrum 
München, German Research Center for 
Environmental Health, by the German Federal 
Ministry of Education and Research and by the 
State of Bavaria. Geno-typing was performed in the 
Genome Analysis Center (GAC) of the Helmholtz 
Zentrum München. The LINUX platform for 
computation was funded by the University of 
Regensburg for the Department of Epidemiology 
and Preventive Medicine at the Regensburg 
University Medical Center. 
MESA [20] 
Prospective 
population-
based 
5955 
Baseline 
cardiovascular 
disease 
excluded 
Baseline 
cardiovascular 
disease 
Serum 
creatinine 
measured at 
baseline and at 
EXAMS 3, 4  
and 5 ; exams 
around 1.5 
years apart 
Vitros analyzer 
(Johnson and 
Johnson) with 
creatine 
aminohydrolas
e method 
MESA and the MESA SHARe project are 
conducted and supported by the National Heart, 
Lung and Blod Institute (NHLBI) in collaboration 
with MESA Investigators.  Support for MESA is 
provided by contracts N01-HC-95159, N01-HC-
95160, N01-HC-95161, N01-HC-95162, N01-HC-
95163, N01-HC-95164, N01-HC-95165, N01-HC-
95166, N01-HC-95167, N01-HC-95168, N01-HC-
95169 and CTSA UL1-RR-024156 
Formatted: Dutch (Belgium)
9 
 
The Rotterdam 
Study-I [21-23]  
Prospective, 
population-
based. 
RS-I: 
5,974 
None 
Any samples with a 
call rate<97.5%, 
excess autosomal 
heterozygosity >0.336 
(~FDR <0.1%), 
mismatch between 
called and phenotypic 
gender, or if there 
were outliers 
identified by the IBS 
clustering analysis 
(see below) with >3 
standard deviations 
from population mean 
or IBS probabilities 
>97% were excluded 
from the analysis. 
Baseline and 
third periodical 
visit: modified 
kinetic Jaffe 
reaction 
Creatinine 
levels were 
measured at 
baseline and at 
the third 
periodical visit.  
Rotterdam Study 1: The GWA study was funded by 
the Netherlands Organisation of Scientific Research 
NWO Investments (nr. 175.010.2005.011, 911-03-
012), the Research Institute for Diseases in the 
Elderly (014-93-015; RIDE2), the Netherlands 
Genomics Initiative (NGI)/Netherlands Consortium 
for Healthy Aging (NCHA) project nr. 050-060-810. 
We thank Pascal Arp, Mila Jhamai, Dr Michael 
Moorhouse, Marijn Verkerk, and Sander Bervoets 
for their help in creating the GWAS database. The 
Rotterdam Study is funded by Erasmus Medical 
Center and Erasmus University, Rotterdam, 
Netherlands Organization for the Health Research 
and Development (ZonMw), the Research Institute 
for Diseases in the Elderly (RIDE), the Ministry of 
Education, Culture and Science, the Ministry for 
Health, Welfare and Sports, the European 
Commission (DG XII), and the Municipality of 
Rotterdam. The authors are very grateful to the 
participants and staff from the Rotterdam Study, the 
participating general practitioners and the 
pharmacists. We would like to thank Dr. Tobias A. 
Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob 
de Graaf as well as their institutions the Erasmus 
Computing Grid, Rotterdam, The Netherlands, and 
especially the national German MediGRID and 
Services@MediGRID part of the German D-Grid, 
both funded by the German Bundes-ministerium für 
Forschung und Technology under grants #01 AK 
803 A-H and #01 IG 07015 G, for access to their 
grid resources. Abbas Dehghan is supported by 
NWO grant (vici, 918-76-619). 
The Study of 
Health in 
Pomerania 
(SHIP) [24,25] 
Prospective 
population-
based 
4,105 None 
The following 
samples were 
excluded: Affymetrix 
QC call rate <86%, 
sample call rate 
<92%, duplicate 
samples (by IBD 
estimation), 
individuals with 
reported/genotyped 
gender mismatch. 
Jaffé method at 
both visits 
Serum 
creatinine was 
measured at 
baseline and at 
the first follow-
up visit. 
SHIP is part of the Community Medicine Research 
net of the University of Greifswald, Germany, which 
is funded by the Federal Ministry of Education and 
Research (grants no. 01ZZ9603, 01ZZ0103, and 
01ZZ0403), the Ministry of Cultural Affairs as well 
as the Social Ministry of the Federal State of 
Mecklenburg-West Pomerania. Genome-wide data 
have been supported by the Federal Ministry of 
Education and Research (grant no. 03ZIK012) and 
a joint grant from Siemens Healthcare, Erlangen, 
Germany and the Federal State of Mecklenburg- 
West Pomerania. The University of Greifswald is a 
member of the ‘Center of Knowledge Interchange’ 
program of the Siemens AG. 
10 
 
Three Cities 
(3C) [26,27] 
Prospective 
population-
based 
6748 None 
DNA samples were 
transferred to the 
French Centre 
National de 
Génotypage (CNG) 
for genotyping. First 
stage samples that 
passed DNA quality 
control were 
genotyped with 
Illumina Human 610-
Quad BeadChips. 
Genotype data were 
retained in the study 
for samples that had 
been successfully 
genotyped for >98% 
of the SNP markers. 
SNPs with call rate 
<98%, minor allele 
frequency<1% or 
exhi-biting departure 
from the Hardy-
Weinberg equilibrium 
in the 3C population 
(p<10
-6
) were 
excluded. We also 
removed 308 
samples because 
they were found to be 
1st or 2nd-degree 
relatives of other 
study partici-pants or 
were assessed non-
European descent 
based on genetic 
analysis. This led us 
to retain 6440 
individuals. 
Jaffe assay 
was used to 
measure 
creatinine in all 
participants at 
baseline and at 
the 4-yr follow-
up.  In order to 
obtain isotope 
dilution mass 
spectrometry 
(IDMS) 
traceable 
creatinine, we 
used    
baseline and 
follow-up  
frozen serum 
samples from 
20% of the 
participants to 
remeasure 
creatinine with 
an IDMS 
traceable 
enzymatic 
assay and 
developed 
equations  
relating the 
Jaffe and 
IDMS-traceable 
creatinine. 
Serum 
creatinine was 
measured at 
baseline and at 
the 4-yr follow-
up. 
 
Three Cities: The work was made possible by the 
generous participation of the control subjects, the 
patients, and their families. We thank Dr. Anne 
Boland (CNG) for her technical help in preparing 
the DNA samples for analyses. This work was 
supported by the National Foundation for 
Alzheimer’s disease and related disorders, the 
Institut Pasteur de Lille and the Centre National de 
Génotypage. The Three-City Study was performed 
as part of a collaboration between the Institut 
National de la Santé et de la Recherche Médicale 
(Inserm), the Victor Segalen Bordeaux II University 
and Sanofi-Synthélabo. The Fondation pour la 
Recherche Médicale funded the preparation and 
initiation of the study. The 3C Study was also 
funded by the Caisse Nationale Maladie des 
Travailleurs Salariés, Direction Générale de la 
Santé, MGEN, Institut de la Longévité, Agence 
Française de Sécurité Sanitaire des Produits de 
Santé, the Aquitaine and Bourgogne Regional 
Councils, Fondation de France and the joint French 
Ministry of Research/INSERM “Cohortes et 
collections de données biologiques” programme. 
Lille Génopôle received an unconditional grant from 
Eisai. 
Stage 2 
cohorts 
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ADVANCE 
[28,29] 
randomised 
controlled 
trial done by 
215 
collaborating 
centres in 20 
countries 
2301 
All patients are 
T2D  of 
Caucasian origin 
None 
Nationally 
approved 
standardized 
tests performed 
at each of the 
participating 
Centers in all 
countries 
Serum 
creatinine was 
measured at 
baseline and at 
the end of the 
study which 
was 5 years 
later.   
ADVANCE: The genetic epidemiological work was 
funded by Prognomix Inc. and by grants  from 
Genome Quebec and Canadian Institutes for Health 
Research (CIHR). The clinical study was managed 
by the George Institute for International Health 
(Sydney, Australia) with grants received from Les 
Laboratoires Servier, France and from  Medical 
Research Council of Australia. The genotyping was 
performed at the genomic platform of CRCHUM.  
The authors acknowledge the technical help of  
Carole Long and  Mounsif Haloui and the 
bioinformatic analyses performed by Gilles 
Godefroid, François-Christophe Blanchet-Marois 
and François Harvey. The members of the genetic 
sub-study  of ADVANCE, Stephen Harrap and 
Michel Marre are also acknowledged. 
Blue Mountains 
Eye Study 
BMES [30-32]  
Prospective 
cohort study 
2,761 
(2534 after 
QC) 
None 
Subjects with missing 
phenotype data or 
whose genotype data 
failed QC 
Baseline Serum 
creatinine was 
measured 
using the 
Roche Jaffe 
assay; at the 
10-year follow-
up visit, it was 
assessed using 
Isotope Dilution 
Mass 
Spectrometry 
(IDMS). The 
CKDGene 
analysis 
protocol 
(Incident CKD 
and Rapid 
Decline 
Analysis Plan 
November 25, 
2011) was 
followed to 
calibrate/conver
t creatinine 
measures at 
baseline to be 
in alignment 
with the 
measures in 
the 10-year visit 
(using IDMS). 
Baseline and 
the 10-year 
follow-up visits 
The Blue Mountains Eye Study (BMES) was 
supported by the Australian National Health & 
Medical Research Council (NHMRC), Canberra 
Australia (NHMRC project grant IDs  974159, 
211069, 302068, and Centre for Clinical Research 
Excellence in Translational Clinical Research in Eye 
Diseases, CCRE in TCR-Eye, grant ID 529923). 
The BMES GWAS and genotyping costs was 
supported by Australian NHMRC, Canberra 
Australia (NHMRC project grant IDs 512423, 
475604 and 529912), and the Wellcome Trust, UK 
as part of Wellcome Trust Case Control Consortium 
2 (A Viswanathan, P McGuffin, P Mitchell, F 
Topouzis, P Foster, grant IDs 085475/B/08/Z and 
085475/08/Z). EGH is supported by the NHMRC 
Fellowship scheme. 
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Cohorte 
Lausannoise 
(CoLauS)  
 
See “stage 1 
cohorts” 
above 
      
HYPERGENES 
[33] 
case-
control and 
prospective 
population 
based 
651 none none 
Serum 
creatinine was 
measured 
using kinetic 
Jaffe reaction 
The samples 
extracted from 
the 
HYPERGENES 
cohort with 
complete 
baseline and 
follow-up 
(mean 5.6 
years)  
information 
were used for 
this analysis 
(651 subjects). 
HYPERGENES (FP7 - HEALTH-F4-2007-201550);  
INTEROMICS (MIUR - CNR Italian Flagship 
Project); IC15-CT98-0329-EPOGH; LSHM-CT-
2006-037093; HEALTH-2011-278249-EU-
MASCARA; and ERC Advanced Grant-2011-
294713-EPLORE and the Fonds voor 
Wetenschappelijk Onderzoek Vlaanderen; Ministry 
of the Flemish Community; Brussels; Belgium 
(grants G.0575.06 and G.0734.09) 
KORA S3/F3 
(non-GWAS) 
[18,19] 
Prospective, 
population-
based 
1498  none 
Individuals not 
genotyped 
genome-wide as 
described under 
“stage 1 cohorts” 
S3: enzymatic 
assay. 
F3: Modified 
kinetic Jaffe 
reaction 
Serum 
creatinine was 
measured at 
baseline and at 
the 10 year 
(F3) follow-up. 
KORA studies: The genetic epidemiological work 
was funded by the NIH subcontract from the 
Children’s Hospital, Boston, US, (H.E.W., I.M.H, 
prime grant 1 R01 DK075787-01A1), the German 
National Genome Research Net NGFN2 and 
NGFNplus (H.E.W. 01GS0823; WK project A3, 
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KORA S4/F4 
(non-GWAS) 
[18,19] 
Prospective, 
population-
based 
1202 none 
Individuals not 
genotyped 
genome-wide as 
described under 
“stage 1 cohorts” 
S4: enzymatic 
assay. 
F5: Modified 
kinetic Jaffe 
reaction 
Serum 
creatinine was 
measured at 
baseline and at 
the 7 year (F4) 
follow-up. 
number 01GS0834), the Munich Center of Health 
Sciences (MC Health) as part of LMUinnovativ, and 
by the Else Kröner-Fresenius-Stiftung 
(P48/08//A11/08 to C.A.B. and B.K.K.; 2012_A147 
to CAB and IMH). The kidney parameter 
measurements in F3 were funded by the Else 
Kröner-Fresenius-Stiftung (C.A.B., B.K.K.) and the 
Regensburg University Medical Center, Germany; 
in F4 by the University of Ulm, Germany (W.K.). 
Genome wide genotyping costs in F3 and F4 were 
in part funded by the Else Kröner-Fresenius-
Stiftung (C.A.B., B.K.K.). De novo genotyping in F3 
and F4 were funded by the Else Kröner-Fresenius-
Stiftung (C.A.B., IMH). The KORA research 
platform and the MONICA Augsburg studies were 
initiated and financed by the Helmholtz Zentrum 
München, German Research Center for 
Environmental Health, by the German Federal 
Ministry of Education and Research and by the 
State of Bavaria. Geno-typing was performed in the 
Genome Analysis Center (GAC) of the Helmholtz 
Zentrum München. The LINUX platform for 
computation was funded by the University of 
Regensburg for the Department of Epidemiology 
and Preventive Medicine at the Regensburg 
University Medical Center. 
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NESDA [34] 
Cohort of 
mostly 
patients with 
a major 
depressive 
or anxiety 
disorder 
1925 
Most individuals 
are patients with 
a major 
depressive or 
anxiety disorder 
none 
Enzymatic 
assay at both 
visits 
Serum 
creatinine was 
measured at 
baseline and at 
follow-up 2 
years later. 
Outliers (>4SD 
from mean) 
were excluded. 
NESDA was supported by the Geestkracht program 
of ZonMW [grant 10-000-1002]; matching funds 
from universities and mental health care institutes 
involved in NESDA. Funding support was also 
provided by the Netherlands Scientific Organization 
(904-61-090, 904-61-193, 480-04-004, 400-05-
717), Centre for Medical Systems Biology (NWO 
Genomics), the Neuroscience Campus Amsterdam 
and the EMGO institute; the European Union 
(EU/WLRT-2001-01254), NIMH (RO1 MH059160). 
Genotyping was funded by the Genetic Association 
Information Network (GAIN) of the Foundation for 
the US National Institutes of Health, and analysis 
were supported by grants from GAIN and the NIMH 
(MH081802) and the Center for Molecular and 
Systems Biology (CMSB). Genotype data were 
obtained from dbGaP 
(http://www.ncbi.nlm.nih.gov/dbgap, accession 
number phs000020.v1.p1. Statistical analyses were 
partly conducted at the Genetic Cluster Computer 
(http://www.geneticcluster.org), which is financially 
supported by the Netherlands Scientific 
Organization (NWO 480-05-003) along with a 
supplement from the Dutch Brain Foundation. 
Popgen [35] 
prospective 
population 
based 577 none none 
Serum 
creatinine was 
measured 
using an 
enzymatic 
assay for 
baseline and at 
the 5-year 
follow-up. 
Serum 
creatinine was 
measured 
using an 
enzymatic 
assay for 
baseline and at 
the 5-year 
follow-up. 
POPGEN: This study was funded by the German 
National Genome Research Network (NGFN; 
Federal Ministry of Education and Research, grant 
numbers 1GS0121, 01GS0171, 01GR0468) and by 
the DFG Excellence Cluster ‘Inflammation at 
Interfaces’ (EXC 306). 
PREVEND (4 
year follow-up) 
[36] 
Prospective 
population-
based 
791 
Enriched for 
higher levels of 
albuminuria 
DM1 and pregnant 
women 
Enzymatic 
assay 
Serum 
creatinine was 
measured at 
baseline and 
follow-up 
screenings; in 
this subset, the 
follow-up took 
place for 4 
years after 
recruitment. 
The PREVEND Study was financially supported by 
several grants from the Dutch Kidney Foundation. 
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PREVEND (9 
year follow-up) 
[36] 
Prospective 
population-
based 
2169 
Enriched for 
higher levels of 
albuminuria 
DM1 and pregnant 
women 
Enzymatic 
assay 
Serum 
creatinine was 
measured at 
baseline and 
follow-up 
screenings, 
that took place 
approximatly 
every three 
years 
 
The PREVEND Study was financially supported by 
several grants from the Dutch Kidney Foundation. 
The Rotterdam 
Study-II [21-23] 
Prospective, 
population-
based. 
1,895 None 
Any samples with a 
call rate<97.5%, 
excess autosomal 
heterozygosity >0.336 
(~FDR <0.1%), 
mismatch between 
called and phenotypic 
gender, or if there 
were outliers 
identified by the IBS 
clustering analysis 
(see below) with >3 
standard deviations 
from population mean 
or IBS probabilities 
>97% were excluded 
from the analysis. 
Baseline and 
the third 
periodical visit: 
enzymatic 
assay 
Creatinine 
levels were 
measured at 
baseline and at 
the third 
periodical visit.  
Rotterdam Study II: The GWA study was funded by 
the Netherlands Organisation of Scientific Research 
NWO Investments (nr. 175.010.2005.011, 911-03-
012), the Research Institute for Diseases in the 
Elderly (014-93-015; RIDE2), the Netherlands 
Genomics Initiative (NGI)/Netherlands Consortium 
for Healthy Aging (NCHA) project nr. 050-060-810. 
We thank Pascal Arp, Mila Jhamai, Dr Michael 
Moorhouse, Marijn Verkerk, and Sander Bervoets 
for their help in creating the GWAS database. The 
Rotterdam Study is funded by Erasmus Medical 
Center and Erasmus University, Rotterdam, 
Netherlands Organization for the Health Research 
and Development (ZonMw), the Research Institute 
for Diseases in the Elderly (RIDE), the Ministry of 
Education, Culture and Science, the Ministry for 
Health, Welfare and Sports, the European 
Commission (DG XII), and the Municipality of 
Rotterdam. The authors are very grateful to the 
participants and staff from the Rotterdam Study, the 
participating general practitioners and the 
pharmacists. We would like to thank Dr. Tobias A. 
Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob 
de Graaf as well as their institutions the Erasmus 
Computing Grid, Rotterdam, The Netherlands, and 
especially the national German MediGRID and 
Services@MediGRID part of the German D-Grid, 
both funded by the German Bundes-ministerium für 
Forschung und Technology under grants #01 AK 
803 A-H and #01 IG 07015 G, for access to their 
grid resources. Abbas Dehghan is supported by 
NWO grant (vici, 918-76-619). 
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SAPHIR [37,38] 
healthy 
working 
population  1726 none 
Of the 1726 subjects 
genotyped, 1374 had 
serum creatinine 
measurements at 
both examinations 
and were thus 
available for the 
current analyses. 
Modified kinetic 
Jaffé reaction 
(CREA®, 
Roche 
Diagnostics 
GmbH, 
Mannheim, 
Ger-many) in 
the serum 
In May 2003 
the first follow-
up examination 
was started. 
Follow-up of 
the study 
population was 
continued until 
2008.  
The SAPHIR-study was partially supported by a 
grant from the Kamillo Eisner Stiftung to B. 
Paulweber and by grants from the "Genomics of 
Lipid-associated Disorders – GOLD" of the 
"Austrian Genome Research Programme GEN-AU" 
to F. Kronenberg.  
Cardiovascular 
risk in Young 
Finns Study 
(YFS) [39]  
population-
based follow 
up-study  
1683 None None 
Serum 
creatinine was 
determined 
spectrophotom
etrically by the 
Jaffé method 
(picric acid; 
Olympus 
Diagnostica 
GmbH) from 
frozen plasma 
samples. 
Serum 
creatinine was 
measured at 
baseline and at 
the 6 year 
follow-up. 
 
The Young Finns Study has been financially 
supported by the Academy of Finland: grants 
134309 (Eye), 126925, 121584, 124282, 129378 
(Salve), 117787 (Gendi), and 41071 (Skidi), the 
Social Insurance Institution of Finland, Kuopio, 
Tampere and Turku University Hospital Medical 
Funds (grant 9M048 and 9N035 for TeLeht), Juho 
Vainio Foundation, Paavo Nurmi Foundation, 
Finnish Foundation of Cardiovascular Research 
and Finnish Cultural Foundation, Tampere 
Tuberculosis Foundation and Emil Aaltonen 
Foundation (T.L). The expert technical assistance in 
the statistical analyses by Ville Aalto and Irina 
Lisinen is gratefully acknowledged. 
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Supplementary Table 2. Study-specific genotyping information for stage 1and stage 2 studies. 
Study Array type 
Genotype 
calling 
Quality control 
filters for 
genotyped SNPs 
used for 
imputation 
No. of 
SNPs used 
for 
imputation 
Imputation 
Imputation 
backbone 
for phased 
CEU 
haplotypes 
(NCBI build) 
Filtering of 
imputed 
genotypes
1
 
Data 
management 
and statistical 
analysis 
Population 
stratification or 
principal 
components 
(PCs) 
Stage 1 
cohorts 
         
AGES 
Illumina 
Hu370CNV 
Illumina 
call rate<97%; 
MAF<1%; 
pHWE<1e-6 
mishap p<1e-9, 
SNPs not in 
Hapmap or 
strandedness 
issues merging 
with Hapmap 
329,804 
MACH 
version 
1.0.16 
HapMap 
release 22 
(build 36) 
none 
R, ProbABEL, 
Linear and 
Logistic 
Regression 
We observed no 
association for 
the tested traits 
with the 10 PCs 
estimated using 
Eigenstrat.
[1]
 
Amish 
Studies 
Affymetrix 
500K 
BRLMM 
call rate<95% 
MAF<1%, 
pHWE<10E-6 
SNPs not in 
Hapmap 
 
338,598 
MACH 
version 
1.0.15 
phased CEU 
haplotypes, 
HapMap 
release 22 
(build 36) 
none 
Measured 
genotype 
accounting for 
polygenic 
component 
NA 
ARIC 
Affymetrix 
6.0 
Birdseed 
call rate <95% 
MAF<1% 
pHWE <10E-5 
669,450 
MACH 
version 
1.0.16 
HapMap 
release 22 
(build 36) 
none 
ProbABEL, 
PLINK, R 
Significant 
association was 
observed 
between some 
of the top 10 
PCs estimated 
using Eigenstrat. 
The appropriate 
PCs were 
therefore 
included in the 
respective 
stratum as 
covariates in the 
association 
analyses  
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ASPS 
Illumina 
Human610-
Quad 
BeadChip 
Illumina 
call rate<98% 
MAF<0.01 
pHWE<1e-6 
mishap p<1e-9 
Mendelian 
errors>100, SNPs 
not in Hapmap or 
strandedness 
issues merging 
with Hapmap 
550,635 
MACH 
version 
1.0.15 
HapMap 
release 22 
(build 36) 
none 
R, linear and 
logistic fixed 
effects model 
NA 
Cardio-
vascular 
Health Study 
(CHS) 
Illumina 
370CNV 
Illumina 
BeadStudio 
call rate<97%, 
MAF<1% 
pHWE<10E-5 
heterozygotes=0; 
SNPs not in 
HapMap 
306,655 
BimBam 
version 
0.99 
HapMap 
CEU release 
22 (build 36) 
dosage 
variance < 
0.01 
Linear and 
logistic 
regression 
using R, 
robust SE 
estimation 
Study sites 
(clinic sites) 
were included as 
covariates in the 
regression to 
account for 
population 
stratification. 
CoLaus 
Affymetrix 
500K 
BRLMM 
Call rate<70%, 
MAF<1% 
pHWE<1E-7 
390,029 
IMPUTE 
version 
0.2.0 
HapMap 
release 21 
(build 35) 
none Matlab 
First 4 ancestry 
PCs were 
significantly 
associated both 
with eGFR and 
CKD, thus were 
included in the 
analysis. 
Framingham 
Heart Study 
(FHS) 
Affymetrix 
500K  
Affymetrix 
50K 
supplement
al 
Affymetrix 
call rate<97% 
pHWE<1e-6 
MAF<1% 
mishap p<1e-9; 
Mendelian 
errors>100; 
SNPs not in 
Hapmap or 
strandedness 
issues merging 
with Hapmap 
378,163 
MACH 
version 
1.0.15 
HapMap 
release 22 
(build 36) 
none 
R, linear mixed 
effect models 
and GEE 
models, robust 
variance 
option to 
account for 
relatedness 
We observed no 
association with 
CKD with the 10 
PCs estimated 
using Eigenstrat. 
Significant 
association 
between eGFR 
and the 10 PCs 
was observed 
therefore, PCs 
were included in 
the analysis for 
association 
between 
genotype and 
eGFR. 
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GENOA 
Affymetrix 
6.0 
(primary), 
Illumina 
610-Quad, 
Illumina 
660-Quad, 
Illumina 1M-
Duo 
Birdseed 
(Affymetrix 
data), 
Genome 
Studio 
(Illumina 
data) 
Call Rate<95%, 
MAF<1%; 
pHWE < 0.001 
1,233,495 
(because of 
the different 
platforms, 
some SNPs 
may have 
had many 
missings) 
MACH 
version 
1.0.16 
HapMap 
release 22 
(build 36), 
CEU 
founders 
none 
R, multic and 
GEE 
Using the PLINK 
--cluster option, 
we did not 
observe any 
population 
stratification (all 
subjects placed 
within the same 
cluster). We did 
not adjust for 
PCs in the 
association 
analysis. 
Health ABC Illumina 1M 
BeadStudio 
v3.3.7 
MAF<1% 
call rate<97% 
pHWE<10
-6
 
914,263 
MACH 
version 
1.0.16 
HapMap 
CEPH 
release 22 
(build 36) 
none 
R, linear and 
logistic 
regression 
models 
Adjust for the 1st 
PC 
Hypergenes 
Illumina 1M 
Duo 
Illumina 
call rate<99%, 
MAF<0.01 
882935 
MACH 
version 1.0 
phased CEU 
haplotypes, 
HapMap 
release 22 
(build 36) 
none 
No 
relatedness 
correct for study 
center 
JUPITER 
Illumina 
Omni 1 
Quad 
Genome 
Studio 
Call rate < 98.5%, 
MAF<1%, 
pHWE<1E-6 
979,089 
MACH 
version 
1.0.15 
1000 
Genomes, 
release 
6/2010 
none R 
Ten PCs from 
EIGENSTRAT 
included 
KORA S3/F3 
Affymetrix 
500K 
BRLMM 
per-chip call rate 
<93%; MAF<5%; 
discrepancy for 
one of the 50 
SNPs common on 
both chips; 
gender checks 
380,407 MACH 
HapMap 
release 22 
(build 35) 
none 
MACH2QTL, 
PROBABEL, 
R, VISUAL 
BASIC 
NA 
KORA S4/F4 
Affymetrix 
6.0 
BRLMM 
per-chip call rate 
<93%; per SNP 
call rate <93%; 
MAF<1%; gender 
checks 
629,893 MACH 
HapMap 
release 22 
(build 36) 
none 
MACH2QTL, 
PROBABEL, 
R, VISUAL 
BASIC 
NA 
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Rotterdam 
Study – I 
Version 3 
Illumina 
Infinium II 
HumanHap5
50 
BeadStudio 
call rate<90%; 
MAF<0.01; 
pHWE<1E-5; 
Mendelian 
errors>100; SNPs 
not in Hapmap or 
strandedness 
issues merging 
with Hapmap 
491,875 MACH 
HapMap 
release 22 
(build 36) 
none ProbABEL NA 
SHIP 
Affymetrix 
6.0 
Affymetrix 
Birdseed2 
none 869,224 
IMPUTE 
version 
0.5.0 
HapMap 
release 22 
(build 36) 
none 
SNPTEST 
v1.1.5, 
QUICKTEST 
v0.94, R, 
InforSense, 
InterSystems 
Caché, SAS 
We observed no 
population 
stratification 
using PCs 
estimated using 
Eigenstrat.
[1]
 
3 City Study 
Illumina 
610K 
Illumina 
Call rate<98%, 
MAF<1%, 
pHWE<1E-6 
537,029 
MACH 
version 
1.0.15 
HapMap 
release 22 
(build 36.3) 
none 
SAS, 
ProbABEL and 
R, linear or 
logistic 
regression  
none 
Stage 2 
cohorts 
         
ADVANCE 
Affymetrix 
5.0 
Affymetrix 
6.0 Affymetrix 
SNPs genotyped 
on affymetrix 5.0: 
call rate <96% 
(<99% if MAF 
<5%); 
 
SNPs genotyped 
on affymetrix 6.0: 
Call rate < 97% 
(<99% if MAF 
<5%) 876688 
IMPUTE2 
v2.1.2 
Impute2 
Website 
1000G Pilot 
(CEU - 
Jun2010) + 
HapMap3 
release 2 (all 
available 
haplotypes – 
Feb2009) 
(build 36) 
YES (SNPs 
with 
imputation 
info < 0.5 
were filtered 
out) 
SNPTEST, 
frequentist 
additive 
model using a 
missing data 
likelihood 
score test 
Eigenstrat. Two 
first principle 
components 
were included in 
the analysis for 
association 
between 
genotype and all 
phenotypes. 
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Blue 
Mountains 
Eye Study 
(BMES) 
Custom 
Illumina 
Infinium 
670k array 
Illumina 
Call rate<95%, 
MAF<1%, 
pHWE<1E-6, 
SNPs not in 
Hapmap or 
strandedness 
issues merging 
with Hapmap 
501,910 
MACH 
version 
1.0.16 
HapMap 
release 22 
(build 36) 
MAF<1% 
Rsq<0.3 
SAS, linear 
and logistic 
models 
No association 
was observed 
between either 
CKD or eGFR 
and the top 4 
dimensions 
estimated using 
multi-
dimensional 
scaling in 
PLINK. 
Therefore no 
ancestry 
dimensions were 
included in the 
analysis for 
association 
between 
genotype and 
either CKD or 
eGFR. 
CoLaus 
Affymetrix 
500K 
BRLMM 
Call rate<70%, 
MAF<1% 
pHWE<1E-7 
390,029 
IMPUTE 
version 
0.2.0 
HapMap 
release 21 
(build 35) 
none Matlab 
First 4 ancestry 
PCs were 
significantly 
associated both 
with eGFR and 
CKD, thus were 
included in the 
analysis. 
HYPERGENE
S 
Illumina 1M 
Duo 
Illumina 
call rate<99%,  
MAF<0.01 
882935 
MACH 
version 1.0 
phased CEU 
haplotypes, 
HapMap 
release 22 
(build 36) 
none 
No 
relatedness 
correct for study 
center 
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NESDA 
Perlegen 
600K, 
Affymetrix 
600K 
Perlegen, 
Birdseed v2 
call 
rate<95%,MAF<1%, 
not mapped, HWE p 
<10^-6, strand 
ambiguities, high 
disconcordance 
between genotyping 
platforms or 
between positive 
controls, non-
random genotypic 
failure, >5% 
Mendelian errors 
435291, 
560631 Beagle 3.04 
HapMap 
release 23 
(build 36) none SNPTEST, R 
First 10 PCs were 
used as covariates 
Popgen 
Affymetrix 
6.0 
Birdseed v2 
sample call rate 
<0.90; SNP call 
rate <0.95; 
MAF<1% 
pHWE<0.0001; 
709,003 
MACH 
version 
1.0.16 
phased CEU 
haplotypes, 
HapMap 
release 22 
(build 36) 
none PLINK, R NA 
PREVEND 
HumanCytoS
NP-12v1 
GenomeStudi
o 
call rate <95%, 
pHWE<0.0001, 
MAF <0.01 
232571 BEAGLE 3.2 
phased CEU 
haplotypes, 
HapMap 
release 22 
(build 36) 
PLINK 1.07 
filters INFO 
<0.1 and MAF 
<0.01 
STATA 11MP, 
PLINK 1.07 
- 
Rotterdam 
Study – II 
Version 3 
Illumina 
Infinium II 
HumanHap5
50 
BeadStudio 
call rate<90% 
MAF<0.01; 
pHWE<1E-5 
Mendelian 
errors>100; SNPs 
not in Hapmap or 
strandedness 
issues merging 
with Hapmap 
495,478 MACH 
HapMap 
release 22 
(build 36) 
none ProbABEL NA 
Cardio-
vascular risk 
in Young 
Finns Study 
(YFS)  
Illumina 
Custom 
BeadChip 
Human670K  
Illumina 
Call rate < 95%, 
MAF<1%, 
pHWE<1E-6, 
pi-hat > 0.2 
removed due to 
possible 
relatedness  
546,677 
MACH 
version 1.0 
HapMap 2 
release 22 
(NCBI build 
36 dbSNP 
126) 
Rsq<0.2 
R, linear mixed 
effect models 
and GEE 
models, robust 
variance 
option to 
account for 
relatedness 
We have used 
multidimensional 
scaling for 
genetic 
stratification and 
included the 
most affecting 
components in 
our model 
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De novo 
genotyping 
Genotyping 
Platform 
Method  QC     
SAPHIR 
Applied 
Biosystems 
7900HT 
Taqman 
PCR 
70 duplicates per SNP: 2 discordants for 
rs11803049, 0 discordants for the other SNPs 
HWE-testing: p>0.05 for all SNPs 
Call rate >98.5% for all SNPs 
    
KORA S3/F3 
(non-GWAS) 
Applied 
Biosystems 
7900HT 
Taqman 
PCR 
18% duplicates per SNP: 0 discordants for all 
SNPs 
HWE-testing: p>0.05 for all SNPs 
Call rate >98.5% for all SNPs 
    
KORA S4/F4 
(non-GWAS) 
Applied 
Biosystems 
7900HT 
Taqman 
PCR 
18% duplicates per SNP: 1 discordants for 
rs11803049, 0 discordants for the other SNPs 
HWE-testing: p>0.05 for all SNPs 
Call rate 97.2% for rs11803049, >99% for all 
other SNPs 
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Supplementary Table 3: Details on kidney function measures over time in each study 
  
CKDi 
cases, 
n 
CKDi25 
cases, 
n 
CKDi 
controls, 
n 
eGFRchange* 
overall 
(ml/min/1.73m
2
 
per year) 
eGFRchange* 
noCKD 
(ml/min/1.73m
2
 per 
year) 
eGFRchange* CKD 
(ml/min/1.73m
2
 per 
year) 
individuals 
with eGFR 
change <0, n 
Rapid3 
overall 
cases, 
n 
Rapid3 
noCKD 
cases, 
n 
Rapid3 
overall 
controls, 
n 
stage 1 cohorts                     
AGES 703 563 2408 0.8 (1.2) 0.8 (1.2) 0.1 (1.2) 597 105 105 3110 
Amish NA NA NA 1.2 (5.3) 1.4 (5.2) NA 192 NA NA NA 
ASPS 53 18 416 1.6 (3.8) 1.8 (3.89  -0.9 (3.0) 137 135 132 381 
KORA3 153 104 1434 0.7 (1.8) 0.8 (1.8) -1.0 (1.9) 511 144 144 1497 
KORA4 94 52 1659 0.6 (3.3) 0.6 (2.3) -0.1 (2.2) 662 222 217 1585 
ARIC 732
A
 435
B
 7793 1.2 (2.6)
C
 1.2 (2.5)  -0.4 (2.5) 2059 1477 1465 7275 
CoLaus 77 27 1778 1.2 (2.5) 1.3 (2.4) -0.5 (2.6) 561 382 378 1549 
FHS 
(Offspring and Cohort) 244 184 2069 0.8 (2.3) 0.9 (2.4) -0.7 (1.4) 931 289 287 2234 
GENOA 54 30 942 0.6 (5.1) 0.7 (5.1) -0.6 (4.2) 451 265 256 776 
HABC 135 81 563 -0.1 (1.9) -0.1 (2.0) -0.2 (1.6) 474 43 40 845 
JUPITER 429 162 5739 1.7 (8.4) 2.2 (8.6) -2.1 (5.2) 2808 2497 2434 4396 
SHIP 165 88 2919 0.4 (3.4) 0.4 (3.4) -0.2 (3.4) 1383 600 582 2603 
The Rotterdam Study 
(RS-I) 283 129 1953 0.9 (2.2) 1.1 (2.2) -0.3 (2.0) 783 371 367 2051 
CHS 224 97 2129 0.4 (3.4) 0.6 (3.5) -0.5 (2.7) 1356 430 397 2390 
MESA 291 70 1723 0.7 (2.2) 0.8 (2.3) 0.1 (1.9) 499 283 270 2041 
3C 282 80 1818 0.6 (3.2) 0.9 (3.2) -0.5 (2.6) 1502 505 467 2084 
  
          
stage 2 cohorts                     
ADVANCE 230 138 1479 -0.2 (5.8) -0.1 (6.0) -0.6 (4.6) 990 457 413 1577 
BMES 275 87 712 0.7 (1.7) 0.7 (1.9) 0.4 (0.8) 342 75 74 1229 
COLAUS 51 15 2081 0.3 (2.5) 0.4 (2.4) -1.3 (3.6) 991 250 246 1959 
HYPERGENES 14 11 633 1.0 (7.5) 1.1 (7.6) -1.4 (1.4) 208 199 199 452 
KORA3 40 30 1191 0.5 (1.9) 0.5 (1.9) -0.5 (1.6) 479 101 101 1169 
KORA4 45 26 1101 0.6 (2.5) 0.7 (2.5) -0.5 (1.7) 444 173 173 1016 
NESDA 8 1 1262 -1.2 (7.7) -1.2 (7.7) 4.1 (4.0) 695 304 296 966 
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popgen 46 14 496 0.9 (2.6) 1.0 (2.6) -0.1 (1.7) 173 83 81 494 
PREVEND 4yrs  17 10  725  -4.1 (6.4)  -4.1 (6.5)  -2.3 (4.0)  566  52  49  739  
PREVEND 9yrs  101  49  2031  0.7 (1.4)  0.7 (1.4)  0.6 (1.1)  604  111  109  2058 
RS-II 177 76 1030 0.9 (1.0) 0.9 (1.0) 0.4 (0.9) 205 56 56 1187 
SAPHIR 33 10 1328 0.7 (2.9) 0.8 (2.9) -2.2 (2.6) 521 244 244 1130 
YFS 2 1 1678 0.8 (2.2) 0.8 (2.2) 0.4 (0.7) 534 160 160 1523 
* A  positive value for eGFRchange indicates a decline eGFR over time, a negative value in eGFRchange indicates a rise in eGFR over time. 
A
 CKDi is defined as the first occurrence of eGFR < 60 at visit 2 or visit 4 
B
 CKD25i is defined as the first occurrence of eGFR < 60 and greater than 25% drop at visit 2 or visit 4 
C
 eGFRchange is calculated as (visit 1 eGFR - visit 4 eGFR)/(age at visit 4 - age at visit 1). If visit 4 eGFR is not available, then visit 2 eGFR and age are 
used. Twenty individuals with eGFRchange beyond 6SD were excluded from all analyses of eGFRchange and Rapid Decline. 
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Supplementary Table 4: 
Association results of rs12917707 at UMOD in stage 1 meta-analysis for all traits analyzed. The effect allele is T, with an allele 
frequency of 0.18. 
trait beta SE pval2GC I2 
eGFRdecline overall 
-
0.15 0.02 2.60E-14 2.7 
eGFRdecline noCKD 
-
0.15 0.02 8.21E-13 0 
eGFRdecline CKD 
-
0.20 0.08 0.01 0 
CKDi 
-
0.20 0.04 9.05E-08 5.5 
CKDi25 
-
0.22 0.05 3.69E-06 18.8 
Rapid3 overall 
-
0.10 0.03 0.0004 0 
Rapid3 noCKD 
-
0.10 0.03 0.0007 0 
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Supplementary Table 5: Imputation scores of SNPs analyzed in stage 1 and stage 2 meta-analysis 
Stage 1 cohorts 
  
SNPID variable Ages Amish Aric Chs Colaus Genoa Habc Jupiter 
Kora3 
GWA 
Kora4 
GWA Mesa Rotterdam Ship 
Three 
Cities ASPS FHS median 
rs1019173 
(GALNTL5/ 
GALNT11) 
oevar_imp 0.98 0.66 0.89 0.98 0.71 0.89 1.00 1.00 0.62 0.88 0.93 0.98 0.87 0.97 0.98 1.01 0.95 
imputed 1 1 1 1 1 1 1 1 1 1 NA 1 1 1 1 1   
used_for_imp 0 0 0 0 0 0 1 0 0 0 NA 0 0 NA 0 1   
rs11764932 
(MEOX2) 
oevar_imp 0.99 0.94 0.99 0.86 0.95 0.99 0.99 0.99 0.98 NA 1.02 1.00 0.99 1.00 1.00 0.96 0.99 
imputed 1 1 1 1 1 1 1 1 1 0 NA 1 0 1 1 1   
used_for_imp 0 0 0 0 0 1 0 0 0 1 NA 0 1 NA 0 0   
rs11803049 
(NPPA/NPPB) 
oevar_imp 0.86 0.78 0.99 0.22 0.70 0.89 1.00 0.99 0.63 NA 1.02 0.98 0.97 1.00 0.98 0.83 0.97 
imputed 1 1 0 1 1 1 1 0 1 0 NA 0 0 1 1 1   
used_for_imp 0 0 1 0 0 1 1 1 0 1 NA 0 1 NA 0 0   
rs12917707 
(UMOD) 
oevar_imp 0.98 0.90 0.94 0.97 0.93 0.91 0.95 0.88 0.86 0.87 0.77 0.98 0.99 0.95 0.96 0.96 0.95 
imputed 1 1 1 1 1 1 1 1 1 1 NA 1 1 1 1 1   
used_for_imp 0 0 0 0 0 1 0 0 0 0 NA 0 0 NA 0 0   
rs759341 
(C2orf48) 
oevar_imp 1.00 0.93 0.97 1.00 0.94 0.98 1.00 0.99 NA NA 0.98 0.99 0.55 0.99 1.00 0.45 0.99 
imputed 1 1 0 0 0 1 1 0 0 0 NA 0 0 1 1 1   
used_for_imp 1 1 1 1 1 0 1 1 1 1 NA 1 1 NA 1 0   
rs875860 
(CDH23) 
oevar_imp 0.73 0.44 0.75 0.22 0.55 0.78 1.00 0.99 0.55 0.72 0.66 0.80 0.73 0.88 0.80 0.63 0.73 
imputed 1 1 1 1 1 1 1 0 1 1 NA 1 1 1 1 1   
used_for_imp 0 0 0 0 0 0 1 1 0 0 NA 0 0 NA 0 0   
rs9814367 
(IL1RAP) 
oevar_imp 0.99 0.99 1.00 0.96 1.00 1.00 1.00 0.88 NA NA 0.97 0.98 0.97 0.43 1.00 1.01 0.99 
imputed 1 1 0 1 0 1 1 1 0 0 NA 1 0 1 1 1   
used_for_imp 0 1 1 0 1 0 0 0 1 1 NA 0 1 NA 0 1   
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stage 2 cohorts 
 
SNPID variable Advance BMES Colaus Hypergenes 
KORAF3 
NGWA 
KORAF4 
NGWA Nesda Popgen Prevend4y Prevend9y 
Rotterdam 
Study II Saphir 
Young 
Finns median 
rs1019173 
(GALNTL5/ 
GALNT11) 
oevar_imp 0.96 0.98 0.71 NA 1.00 1.00 0.92 0.89 0.96 1.02 0.98 1.00 0.99 0.96 
imputed NA NA NA NA 0 0 NA NA 1 1 NA 0 NA   
used_for_imp 0 0 0 1 0 0 1 0 1 1 0 0 0   
rs11764932 
(MEOX2) 
oevar_imp 1.00 0.99 0.95 0.99 1.00 1.00 0.98 1.00 0.84 0.92 0.99 1.00 0.99 0.99 
imputed NA NA NA 1 0 0 NA NA 1 1 NA 0 NA   
used_for_imp 1 0 0 0 0 0 1 0 0 0 0 0 0   
rs11803049 
(NPPA/NPPB) 
oevar_imp 1.00 1.00 0.72 1.00 1.00 1.00 0.98 0.99 0.66 0.63 0.98 1.00 NA 0.98 
imputed NA NA NA 1 0 0 NA NA 1 1 NA 0 NA   
used_for_imp 1 1 0 0 0 0 1 0 0 0 0 0 NA    
rs12917707 
(UMOD) 
oevar_imp 0.83 0.96 0.93 1.00 1.00 1.00 0.88 0.92 0.45 0.46 0.98 1.00 0.88 0.90 
imputed NA NA NA 1 0 0 NA NA 1 1 NA 0 NA   
used_for_imp 0 0 0 0 0 0 0 0 0 0 0 0 0   
rs759341 
(C2orf48) 
oevar_imp 1.00 0.99 0.96 NA 1.00 1.00 0.84 0.98 0.09 0.09 0.99 1.00 NA 0.99$ 
imputed NA NA NA NA 0 0 NA NA 1 1 NA 0 NA   
used_for_imp 1 1 1 1 0 0 1 1 0 0 1 0 NA    
rs875860 
(CDH23) 
oevar_imp 0.83 0.80 0.53 NA 1.00 1.00 0.68 0.71 0.03 0.03 0.80 1.00 0.81 0.80* 
imputed NA NA NA NA 0 0 NA NA 1 1 NA 0 NA   
used_for_imp 0 0 0 1 0 0 0 0 0 0 0 0 0   
rs9814367 
(IL1RAP) 
oevar_imp 1.00 0.97 1.00 1.00 1.00 1.00 1.00 1.00 0.94 1.02 0.97 1.00 0.99 1.00 
imputed NA NA NA 1 0 0 NA NA 1 1 NA 0 NA   
used_for_imp 1 0 1 0 0 0 1 0 0 0 0 0 0   
For each SNP, information on the imputation score ("oevar_imp"), on whether the SNP was imputed ("imputed") and on whether the SNP was used for imputation ("used_for_imp") is shown. “1” 
indicates “yes”, “0” indicates “no”. “NA”: information not provided by study. 
* median of studies participating in eGFRdecline_CKD stage 2 meta-analysis (ADVANCE, BMES, COLAUS, RS-II) 
$ median of studies participating in CKDi25 stage 2 meta-analysis (ADVANCE, BMES, RS-II) 
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Supplementary Table 6:   Morpholino sequences 
 
 
Target gene ATG or splice MO Sequence 
cdh23 Splice 5’ CTCCCGAACCTTCACACCACGACAT 3’ 
galnt11 ATG 5’ AGTAGCGCAGAGTGACGCTGCCCAT 3’ 
prkag2 ATG 5’ AGTCCATCACTGTACTTCCCATTTT 3’ 
mll3a Splice 5’ TGTGCAGTAAGATGTTTACCTGCTT 3’ 
mll3b Splice 5’ ACATTTACTTCTGGTTTGACCTCTT 3’ 
umod ATG 5' CATGTTGACTGATTTTGATGGCTGA 3' 
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Supplementary Figure 1: Genome-wide log10 P value and QQ plots of stage 1 meta-analysis for each trait. 
Genetic loci moved forward to stage 2 meta-analysis are highlighted in orange in the trait they were identified in. 
 
 
Supplementary Figure 1a: Genome-wide log10 P value plot of stage 1 meta-analysis of eGFRchange in the overall sample. 
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Supplementary Figure 1b: Genome-wide log10 P value plot of stage 1 meta-analysis of eGFRchange in those without CKD at 
baseline. 
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Supplementary Figure 1c: Genome-wide log10 P value plot of stage 1 meta-analysis of eGFRchange in those with CKD at 
baseline. 
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Supplementary Figure 1d: Genome-wide log10 P value plot of stage 1 meta-analysis of Rapid Decline in the overall sample. 
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Supplementary Figure 1e: Genome-wide log10 P value plot of stage 1 meta-analysis of Rapid Decline in those without CKD at 
baseline. 
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Supplementary Figure 1f: Genome-wide log10 P value plot of stage 1 meta-analysis of incident CKD. 
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Supplementary Figure 1g: Genome-wide log10 P value plot of stage 1 meta-analysis of CKDi25. 
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Supplementary Figure 1h: Quantile-Quantile plots of stage 1 meta-analyses. 
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